Cargando…

Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations

Physiologically‐based pharmacokinetic (PBPK) modeling has been extensively used to quantitatively translate in vitro data and evaluate temporal effects from drug–drug interactions (DDIs), arising due to reversible enzyme and transporter inhibition, irreversible time‐dependent inhibition, enzyme indu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taskar, Kunal S., Pilla Reddy, Venkatesh, Burt, Howard, Posada, Maria M., Varma, Manthena, Zheng, Ming, Ullah, Mohammed, Emami Riedmaier, Arian, Umehara, Ken‐ichi, Snoeys, Jan, Nakakariya, Masanori, Chu, Xiaoyan, Beneton, Maud, Chen, Yuan, Huth, Felix, Narayanan, Rangaraj, Mukherjee, Dwaipayan, Dixit, Vaishali, Sugiyama, Yuichi, Neuhoff, Sibylle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232864/ https://www.ncbi.nlm.nih.gov/pubmed/31628859 http://dx.doi.org/10.1002/cpt.1693

Ejemplares similares

More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter‐Mediated Clearances
por: Emami Riedmaier, Ariane, et al.
Publicado: (2016)

Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis
por: Burt, Howard J., et al.
Publicado: (2016)

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome
por: Harwood, Matthew D., et al.
Publicado: (2023)

Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney
por: Asaumi, Ryuta, et al.
Publicado: (2022)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Prediction of Metabolite‐to‐Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model
por: Callegari, Ernesto, et al.
Publicado: (2020)

Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
por: Doki, Kosuke, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
por: Shebley, Mohamad, et al.
Publicado: (2018)

Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations
por: Huth, Felix, et al.
Publicado: (2019)

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates
por: Pan, Xian, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling
por: Costales, Chester, et al.
Publicado: (2021)

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
por: Murata, Yukiko, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug
por: Salem, Farzaneh, et al.
Publicado: (2023)

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions
por: Mochizuki, Tatsuki, et al.
Publicado: (2022)

Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug–Drug Interactions
por: Antonescu, Irina E., et al.
Publicado: (2020)

Therapeutic options in coronavirus treatment: COVID-19 drug discovery update
por: Mukherjee, Suchetana, et al.
Publicado: (2022)

Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective
por: Riedmaier, Arian Emami, et al.
Publicado: (2020)

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions
por: Hahn, Martina, et al.
Publicado: (2021)

Assessment of various veterinary drug residues in animal originated food products
por: Parmar, Jagdish Kumar, et al.
Publicado: (2021)

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
por: Nakayama, Shinji, et al.
Publicado: (2023)

Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report
por: Al Shoyaib, Abdullah, et al.
Publicado: (2023)

A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine
por: Jamei, M., et al.
Publicado: (2013)

Drugging the undruggables: exploring the ubiquitin system for drug development
por: Huang, Xiaodong, et al.
Publicado: (2016)

Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions
por: Gill, Jaidip, et al.
Publicado: (2022)

Recent Advances in Drug Therapy for Parkinson's Disease
por: Murakami, Hidetomo, et al.
Publicado: (2022)

LMD-01. Quantifying intrathecal drug delivery utilizing programmable ventriculoperitoneal shunts
por: McThenia, Sheila, et al.
Publicado: (2021)

IMMU-15. QUANTIFYING INTRATHECAL DRUG DELIVERY UTILIZING PROGRAMMABLE VENTRICULOPERITONEAL SHUNTS
por: McThenia, Sheila, et al.
Publicado: (2021)

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Avicenna’s contribution to mechanisms of cardiovascular drugs
por: Javadi, Behjat, et al.
Publicado: (2015)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

Chemical Inhibitors Targeting the Histone Lysine Demethylase Families with Potential for Drug Discovery
por: Das, Nando Dulal, et al.
Publicado: (2023)

Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development
por: Burt, T, et al.
Publicado: (2016)

Translating the Genome into Drugs
por: Dixit, Anjali, et al.
Publicado: (2023)

Unusual and Interesting Adverse Cutaneous Drug Reactions
por: Masatkar, Vaishali, et al.
Publicado: (2018)

Histoire de mots : culture et civilisation /
por: Bénéton, Philippe
Publicado: (1975)

Development and characterization of novel hydrogel containing antimicrobial drug for treatment of burns
por: Thakkar, Vaishali, et al.
Publicado: (2016)

Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib
por: Posada, Maria M., et al.
Publicado: (2017)

Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction
por: Yamazaki, Shinji, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7ja1d0he62osl1egi5d7adl97k